Distribution of Fos-like immunoreactivity in guinea-pig brain following administration of the neurokinin-1 receptor agonist, [Sar9,Met(O2)11]substance P

Neuroscience

Volumn 94, Issue 2, 1999, Pages 663-673

  Yip, J ^a   Chahl, L A ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Sar9,Met(O2)11 substance P; Fos immunohistochemistry; Guinea pig brain; NK1 receptor; SR 140333; Tachykinin

Indexed keywords

NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; NOLPITANTIUM; SUBSTANCE P DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN REGION; CONTROLLED STUDY; DIENCEPHALON; DOG; FEMALE; GUINEA PIG; IMMUNOREACTIVITY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LOCOMOTION; MALE; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR DENSITY; TELENCEPHALON;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CEREBRAL VENTRICLES; GENES, FOS; GUINEA PIGS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; MOTOR ACTIVITY; ORGAN SPECIFICITY; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-FOS; QUINUCLIDINES; RECEPTORS, NEUROKININ-1; REFERENCE VALUES; SUBSTANCE P; TYROSINE 3-MONOOXYGENASE;

EID: 0032835101     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(99)00283-3     Document Type: Article

References (31)

1. Belvisi M.G., Patacchini R., Barnes P.J., Maggi C.A. Facilitatory effects of selective agonists for tachykinin receptors on cholinergic neurotransmission: evidence for species differences. Br. J. Pharmac. 111:1994;103-110.
2. 1 receptor antagonist, CP 99994, in ferrets. Eur. J. Pharmac. 249:1993;R3-R4.
3. Brent P.J., Johnston P.A., Chahl L.A. Plasma catecholamine concentrations during morphine withdrawal in conscious guinea-pigs. Clin. exp. Pharmac. Physiol. 14:1987;623-631.
4. Couture R., Boucher S., Picard P., Regoli D. Receptor characterization of the spinal action of neurokinins in nociception: a three receptor hypothesis. Regul. Pept. 46:1993;426-429.
5. Culman J., Unger T. Central tachykinins - mediators of defence reaction and stress reactions. Can. J. Physiol. Pharmac. 73:1995;885-891.
6. Culman J., Klee S., Ohlendorf C., Unger T. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioural responses to stress. J. Pharmac. exp. Ther. 280:1997;238-246.
7. Dam T.-V. and Quirion R. (1994) Comparative distribution of receptor types in the mammalian brain. In The Tachykinin Receptors (ed. Buck S. H.), pp. 101-123. Humana, Clifton, NJ.
8. De Felipe C., Herrero J.F., O'Brien J.A., Palmer J.A., Doyle C.A., Ure J.M., Smith A.J.H., Laird J.M.A., Belmonte C., Cervero F., Hunt S.P. Altered nociception, analgesia and agression in mice lacking the receptor for substance P. Nature. 392:1998;394-397.
9. Elliott P.J., Iversen S.D. Behavioural effects of tachykinins and related peptides. Brain Res. 381:1986;68-76.
10. Elliott P.J., Mason G.S., Stephens-Smith M., Hagan R.M. Behavioural and biochemical responses following activation of midbrain dopamine pathways by receptor selective neurokinin agonists. Neuropeptides. 19:1991;119-126.
11. 3 receptor. Pharmac. Lett. 56:1995;27-32.
12. Hsu S.M., Soban E. Colour modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J. Histochem. Cytochem. 30:1982;1079-1082.
13. Iyengar S., Gitter B. D., Helton D. R. and Kallman M. J. (1997) Neurokinin-1 receptors mediate anxiety-associated behaviour. Proceedings of the International Tachykinin Conference: Tachykinins in Health and Disease, p. 45. Cairns, Newcastle, Australia.
14. Johnston P.A., Chahl L.A. Tachykinin antagonists inhibit the morphine withdrawal response in guinea-pigs. Naunyn-Schmiedeberg's Arch. Pharmac. 343:1991;283-288.
15. Kramer M.S., Cutler N., Feighner J., Shrivasta R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlson E.J., Hargreaves R.J., Rupniak N.M.J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645.
16. Lieberman D.N., Mody I. Substance P enhances NMDA channel function in hippocampal dentate gyrus granule cells. J. Neurophysiol. 80:1998;113-119.
17. Longmore J., Hill R.G., Hargreaves R.J. Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can. J. Physiol. Pharmac. 75:1997;612-621.
18. Miller A.D., Leslie R.A. The area postrema and vomiting. Front. Neuroendocr. 15:1994;301-320.
19. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. A. Rev. Neurosci. 14:1991;421-451.
20. Nakanishi S. Mammalian tachykinin receptors. A. Rev. Neurosci. 14:1991;123-136.
21. Nutt D. Substance-P antagonists: a new treatment for depression? Lancet. 352:1998;1644-1646.
22. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic, Sydney.
23. 3 receptor agonists in the guinea-pig. Br. J. Pharmac. 116:1995;2496-2502.
24. Regoli D., Boudon A., Fauchére J.-L. Receptors and antagonists for substance P and related peptides. Physiol. Rev. 46:1994;551-599.
25. Suehiro Y., Saito R., Migita K., Hori N. and Hashiguchi T. (1997) Roles of the tachykinin NK-1 receptor in anti-emetic action in ferrets. Proceedings of the International Tachykinin Conference: Tachykinins in Health and Disease, p. 43. Cairns, Newcastle, Australia.
26. 1 receptor antagonist CP99994 attenuates cisplatin induced emesis in the ferret. Eur. J. Pharmac. 250:1993;R5-R6.
27. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 35:1996;1121-1129.
28. Teixeira R.M., Santos A.R., Riberio S.J., Calixto J.B., Rae G.A., De Lima T.C. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behaviour in mice. Eur. J. Pharmac. 311:1996;7-14.
29. Walpole C.S., Brown M.C., James I.F., Campbell E.A., McIntyre P., Docherty R., Ko S., Hedley L., Ewan S., Buchheit K.H., Urban L.A. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br. J. Pharmac. 124:1998;83-92.
30. 3 tachykinin receptor agonist, senktide, in the guinea-pig brain. Br. J. Pharmac. 122:1997;715-725.
31. 1) receptor antagonist (+)-CP-96,345 causes sedation and motor impairment in Swiss albino mice in the black and white box behavioural paradigm. Neurosci. Lett. 143:1992;169-172.